Acetamides

• 

  Subject Areas on Research

  • A closer inspection of tedizolid - authors' reply. 
  • A continuously monitored spectrophotometric assay of glycosidases with nitrophenyl glycosides. 
  • A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. 
  • A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. 
  • A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections. 
  • A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells. 
  • Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. 
  • Assessment of the effects of lacosamide on sleep parameters in healthy subjects. 
  • Clinical management of Staphylococcus aureus bacteremia: a review. 
  • Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. 
  • Colonisation with vancomycin- and linezolid-resistant Enterococcus faecium in a university hospital: molecular epidemiology and risk factor analysis. 
  • Community-Acquired Pneumonia in Adults: Diagnosis and Management. 
  • Differentiation of erythroleukemia cells in vitro: properties of chemical inducers. 
  • Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. 
  • Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. 
  • Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. 
  • Host gene expression profiling and in vivo cytokine studies to characterize the role of linezolid and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) murine sepsis model. 
  • Inducers of Friend leukaemic cell differentiation in vitro--effects of in vivo administration. 
  • Lacosamide improves outcome in a murine model of traumatic brain injury. 
  • Lacosamide in status epilepticus: Update on the TRENdS study. 
  • Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial. 
  • Mast cell modulation of immune responses to bacteria. 
  • Melatonin and agomelatine for preventing seasonal affective disorder. 
  • New treatments for methicillin-resistant Staphylococcus aureus. 
  • Novel tricyclic inhibitors of IKK2: discovery and SAR leading to the identification of 2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide (BMS-066). 
  • Optimizing therapy for methicillin-resistant Staphylococcus aureus bacteremia. 
  • Oseltamivir resistance during treatment of influenza A (H5N1) infection. 
  • Periodic, partial inhibition of IkappaB Kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritis. 
  • Quantitative structure-activity relationship (QSAR) of indoloacetamides as inhibitors of human isoprenylcysteine carboxyl methyltransferase. 
  • Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. 
  • Renal tubular carcinoma; animal model: chemically induced renal tubular carcinoma in rats. 
  • Respiration and osmoregulation of the estuarine crab, Rhithropanopeus harrisii (Gould): effects of the herbicide, alachlor. 
  • Safety, tolerability, and efficacy of GSK1322322 in the treatment of acute bacterial skin and skin structure infections. 
  • Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening. 
  • Successful treatment of right-sided prosthetic valve endocarditis due to methicillin-resistant teicoplanin-heteroresistant Staphylococcus aureus with linezolid. 
  • Surgical site infection prophylaxis strategies for cardiothoracic surgery: a decision-analytic model. 
  • Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. 
  • Treatment of Recurrent Electrographic Nonconvulsive Seizures (TRENdS) study. 
• 

  Keywords of People

  • Laskowitz, Daniel Todd, Professor of Neurology, Duke Innovation & Entrepreneurship
  • Muir, Kelly Walton, Associate Professor of Ophthalmology, Ophthalmology, Glaucoma